AbbVie and Boehringer Ingelheim Discuss M&A Strategies

AbbVie and Boehringer Ingelheim are currently discussing mergers and acquisitions strategies with financial advisory firms. During a recent congress, a Boehringer Ingelheim executive noted that signing an M&A deal does not create value, but rather sets the stage for value creation later. An AbbVie executive added that M&A requires strong conviction from the executive team to be pursued.

The discussions highlight the competitive nature of the pharmaceutical industry, where both AbbVie and Boehringer Ingelheim are actively pursuing strategic growth. AbbVie has previously executed large acquisitions, including Apogee Therapeutics for $10.9 billion and Kestrel Therapeutics for $1.45 billion, demonstrating its M&A approach.